Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Evista
Evista 60 mg film coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-088373 · Präparat HOS-083635
Raloxifene has no effect on the pharmacokinetics of methylprednisolone given as a single dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylprednisolone (HOS-088374)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-01T12:30:00Z · SHA-256 f4ce424f62210f59bcb50c6293efacced149e50104e46c80a22544ef7153a17d · Passage df474a5ce3eae825f2bb61d986e5e6e05b295d4311abf17d9d2e7df109a6302d · Zeichen 615–709 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090627 · Präparat HOS-084095
No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the
following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine,
prednisolone, and trimethoprim/sulfamethoxazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) prednisolone (HOS-086337) nifedipine (HOS-086289) trimethoprim (HOS-085184) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) digoxin (HOS-086172) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 0561145e72ae08336c293749a32c9afef82d758d8dcade48e65d208f6748281b · Zeichen 6798–7049 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090690 · Präparat HOS-084095
No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the
following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine,
prednisolone, and trimethoprim/sulfamethoxazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) prednisolone (HOS-086337) nifedipine (HOS-086289) trimethoprim (HOS-085184) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) digoxin (HOS-086172) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 0561145e72ae08336c293749a32c9afef82d758d8dcade48e65d208f6748281b · Zeichen 6745–6996 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-112513 · Präparat HOS-093697
Methylprednisolone: The usual intravenously administered methylprednisolone dose should be
reduced approximately 25 %, and the usual oral methylprednisolone dose should be reduced
approximately 50 % when co-administered with EMEND 125 mg/80 mg regimen. EMEND, when
given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of
methylprednisolone, a CYP3A4 substrate, by 1.3-fold on Day 1 and by 2.5-fold on Day 3, when
methylprednisolone was co-administered intravenously as 125 mg on Day 1 and orally as 40 mg on
Days 2 and 3.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylprednisolone (HOS-088374)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 59781c74216d4079194431715d8c7acbee52c818e59b60fe0a66823e22d3382e · Zeichen 2235–2790 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-112515 · Präparat HOS-093697
During continuous treatment with methylprednisolone, the AUC of methylprednisolone may decrease
at later time points within 2 weeks following initiation of the EMEND dose, due to the inducing effect
of aprepitant on CYP3A4. This effect may be expected to be more pronounced for orally administered
methylprednisolone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylprednisolone (HOS-088374)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 5f9b0be6e61f834b27c340fe43f036912982c7910d52d7e36712dce24757325e · Zeichen 2792–3109 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22
HOS-112574 · Präparat HOS-093697
Methylprednisolone: The usual intravenously administered methylprednisolone dose should be
reduced approximately 25 %, and the usual oral methylprednisolone dose should be reduced
approximately 50 % when co-administered with EMEND 125 mg/80 mg regimen. EMEND, when
given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of
methylprednisolone, a CYP3A4 substrate, by 1.3-fold on Day 1 and by 2.5-fold on Day 3, when
methylprednisolone was co-administered intravenously as 125 mg on Day 1 and orally as 40 mg on
Days 2 and 3.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylprednisolone (HOS-088374)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 59781c74216d4079194431715d8c7acbee52c818e59b60fe0a66823e22d3382e · Zeichen 2179–2734 im Abschnitt
Wechselwirkungen · Emend
EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22
HOS-112575 · Präparat HOS-093697
During continuous treatment with methylprednisolone, the AUC of methylprednisolone may decrease
at later time points within 2 weeks following initiation of the EMEND dose, due to the inducing effect
of aprepitant on CYP3A4. This effect may be expected to be more pronounced for orally administered
methylprednisolone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylprednisolone (HOS-088374)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 5f9b0be6e61f834b27c340fe43f036912982c7910d52d7e36712dce24757325e · Zeichen 2736–3053 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 12–13
HOS-116835 · Präparat HOS-094481
12
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Products known to have high Tacrolimus is extensively bound to Monitor tacrolimus whole
affinity for plasma proteins, plasma proteins. Possible blood trough concentrations
e.g.: NSAIDs, oral interactions with other active and adjust tacrolimus dose if
anticoagulants, oral substances known to have high needed [see section 4.2].
antidiabetics affinity for plasma proteins should
be considered.
Prokinetic agents: May increase tacrolimus whole Monitor tacrolimus whole
metoclopramide, cimetidine blood trough concentrations and blood trough concentrations
and magnesium-aluminium- increase the risk of serious adverse and reduce tacrolimus dose if
hydroxide reactions (e.g., neurotoxicity, QT needed [see section 4.2].
prolongation). Monitor closely for renal
function, for QT prolongation
with ECG, and for other side
effects.
Maintenance doses of May decrease tacrolimus whole Monitor tacrolimus whole
corticosteroids blood trough concentrations and blood trough concentrations
increase the risk of rejection [see and increase tacrolimus dose if
section 4.4]. needed [see section 4.2].
Monitor graft function closely.
High dose prednisolone or May have impact on tacrolimus Monitor tacrolimus whole
methylprednisolone blood levels (increase or decrease) blood trough concentrations
when administered for the treatment and adjust tacrolimus dose if
of acute rejection. needed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) cimetidine (HOS-085835) methylprednisolone (HOS-088374) metoclopramide (HOS-090626)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage f994c256807d2f2429ef1b7356333972fef6e5d4d1814235ca14f2b2cb0cbeec · Zeichen 13372–15739 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 12–13
HOS-209770 · Präparat HOS-154375
12
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
dose may need to be adjusted
gradually. Monitor graft function
closely.
Moderate CYP3A4 inducers: May decrease tacrolimus Monitor tacrolimus whole blood
metamizole, phenobarbital, whole blood trough trough concentrations and
isoniazid rifabutin, efavirenz, concentrations and increase increase tacrolimus dose if needed
etravirine, nevirapine; weak the risk of rejection [see [see section 4.2].
CYP3A4 inducers: section 4.4]. Monitor graft function closely.
flucloxacillin
Caspofungin May decrease tacrolimus Monitor tacrolimus whole blood
whole blood trough trough concentrations and
concentrations and increase increase tacrolimus dose if needed
the risk of rejection. [see section 4.2]. Monitor graft
Mechanism of interaction has function closely.
not been confirmed.
Cannabidiol (P-gp inhibitor) There have been reports of Tacrolimus and cannabidiol
increased tacrolimus blood should be co-administered with
levels during concomitant caution, closely monitoring for
use of tacrolimus with side effects. Monitor tacrolimus
cannabidiol. This may be due whole blood trough
to inhibition of intestinal P- concentrations and adjust the
glycoprotein, leading to tacrolimus dose if needed [see
increased bioavailability of sections 4.2 and 4.4].
tacrolimus.
Products known to have high Tacrolimus is extensively Monitor tacrolimus whole blood
affinity for plasma proteins, bound to plasma proteins. trough concentrations and adjust
e.g.: NSAIDs, oral Possible interactions with tacrolimus dose if needed [see
anticoagulants, oral other active substances section 4.2].
antidiabetics known to have high affinity
for plasma proteins should be
considered.
Prokinetic agents: May increase tacrolimus Monitor tacrolimus whole blood
metoclopramide, cimetidine whole blood trough trough concentrations and reduce
and magnesium-aluminium- concentrations and increase tacrolimus dose if needed [see
hydroxide the risk of serious adverse section 4.2].
reactions (e.g., neurotoxicity, Monitor closely for renal
QT prolongation). function, for QT prolongation
with ECG, and for other side
effects.
Maintenance doses of May decrease tacrolimus Monitor tacrolimus whole blood
corticosteroids whole blood trough trough concentrations and
concentrations and increase increase tacrolimus dose if needed
the risk of rejection [see [see section 4.2].
section 4.4]. Monitor graft function closely.
High dose prednisolone or May have impact on Monitor tacrolimus whole blood
methylprednisolone tacrolimus blood levels trough concentrations and adjust
(increase or decrease) when tacrolimus dose if needed.
administered for the
treatment of acute rejection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) caspofungin (HOS-109306) phenobarbital (HOS-085617) cimetidine (HOS-085835) rifabutin (HOS-086262) methylprednisolone (HOS-088374) metoclopramide (HOS-090626) etravirine (HOS-088088) cannabidiol (HOS-090609) efavirenz (HOS-087947) nevirapine (HOS-088064) isoniazid (HOS-088590)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 0bb41e9b2822415bed45aeaa4baedfb69482463d056111334a789f729ecfd9cf · Zeichen 11046–15555 im Abschnitt
Wechselwirkungen · RoActemra
RoActemra 20 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 12
HOS-120235 · Präparat HOS-095117
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are
individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 (e.g. methylprednisolone,
dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin,
calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or
benzodiazepines) must be monitored as doses may need to be increased to maintain therapeutic effect.
Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may
persist for several weeks after stopping therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) methylprednisolone (HOS-088374) theophylline (HOS-085910) phenprocoumon (HOS-091031) calcium (HOS-085615) dexamethasone (HOS-084535) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage 5813b1ce7c89db40984eac0f484f563bb69e2bde00d02c31bf6f777b49aba5a3 · Zeichen 1045–1677 im Abschnitt
Wechselwirkungen · RoActemra
RoActemra 162 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 45
HOS-120315 · Präparat HOS-095117
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are
individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 (e.g. methylprednisolone,
dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin,
calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or
benzodiazepines) must be monitored as doses may need to be increased to maintain therapeutic effect.
Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may
persist for several weeks after stopping therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) methylprednisolone (HOS-088374) theophylline (HOS-085910) phenprocoumon (HOS-091031) calcium (HOS-085615) dexamethasone (HOS-084535) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage 5813b1ce7c89db40984eac0f484f563bb69e2bde00d02c31bf6f777b49aba5a3 · Zeichen 1102–1734 im Abschnitt
Wechselwirkungen · RoActemra
RoActemra 162 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 80
HOS-120388 · Präparat HOS-095117
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are
individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 (e.g. methylprednisolone,
dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin,
calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or
benzodiazepines) must be monitored as doses may need to be increased to maintain therapeutic effect.
Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may
persist for several weeks after stopping therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) methylprednisolone (HOS-088374) theophylline (HOS-085910) phenprocoumon (HOS-091031) calcium (HOS-085615) dexamethasone (HOS-084535) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage 5813b1ce7c89db40984eac0f484f563bb69e2bde00d02c31bf6f777b49aba5a3 · Zeichen 1102–1734 im Abschnitt
Wechselwirkungen · Raloxifene Teva
Raloxifene Teva 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-210830 · Präparat HOS-154595
Raloxifene has no effect on the pharmacokinetics of methylprednisolone given as a single dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylprednisolone (HOS-088374)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-09-27T11:30:00Z · SHA-256 bbf6706a7418bb5343336909f5773d58520cc2fd4c0b1b303b9821080fd9b117 · Passage df474a5ce3eae825f2bb61d986e5e6e05b295d4311abf17d9d2e7df109a6302d · Zeichen 619–713 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-132872 · Präparat HOS-097310
13
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Dexamethasone, Potential ↑in plasma concentrations of Careful monitoring.
fluticasone, these drugs Dose adjustment of these medicinal
methylprednisolone products may be required.
Lipid Lowering Drugs
Lovastatin, simvastatin, Potential ↑in plasma concentrations of Contraindicated due to an increased
atorvastatin* these drugs risk of skeletal muscle toxicity,
including rhabdomyolysis (see
section 4.3).
Respiratory Drugs
Salmeterol Salmeterol Not recommended due to an
AUC: ↑ 15-fold increased risk in QT prolongation.
Cmax: ↑ 1.4-fold
Urological Drugs
Fesoterodine Fesoterodine active metabolite: Not recommended due to an
Tolterodine AUC: ↑ 2.3-fold increased risk of QT prolongation.
Solifenacin Cmax: ↑ 2.0-fold Fesoterodine and solifenacin are
contraindicated in patients with renal
Solifenacin: impairment (see section 4.3).
AUC: ↑ 3.0-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): solifenacin (HOS-116433) tolterodine (HOS-087792) fluticasone (HOS-108914) lovastatin (HOS-086157) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) simvastatin (HOS-086158) salmeterol (HOS-086285) dexamethasone (HOS-084535) fesoterodine (HOS-116432)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage c1a5069997a87321e46bd8aff4444df27aef883235aeff401c7a8ea1faec7fc9 · Zeichen 27524–29247 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 13–14
HOS-139179 · Präparat HOS-098290
13
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Products known to have high Tacrolimus is extensively bound to Monitor tacrolimus whole
affinity for plasma proteins, plasma proteins. Possible blood trough concentrations
e.g.: NSAIDs, oral interactions with other active and adjust tacrolimus dose if
anticoagulants, oral substances known to have high needed (see section 4.2).
antidiabetics affinity for plasma proteins should
be considered.
Prokinetic agents: May increase tacrolimus whole Monitor tacrolimus whole
metoclopramide, cimetidine blood trough concentrations and blood trough concentrations
and magnesium-aluminium- increase the risk of serious adverse and reduce tacrolimus dose if
hydroxide reactions (e.g., neurotoxicity, QT needed (see section 4.2).
prolongation). Monitor closely for renal
function, for QT prolongation
with ECG, and for other side
effects.
Maintenance doses of May decrease tacrolimus whole Monitor tacrolimus whole
corticosteroids blood trough concentrations and blood trough concentrations
increase the risk of rejection (see and increase tacrolimus dose if
section 4.4). needed (see section 4.2).
Monitor graft function closely.
High dose prednisolone or May have impact on tacrolimus Monitor tacrolimus whole
methylprednisolone blood levels (increase or decrease) blood trough concentrations
when administered for the treatment and adjust tacrolimus dose if
of acute rejection. needed.
Direct-acting antiviral (DAA) May have impact on the Monitor tacrolimus whole
therapy pharmacokinetics of tacrolimus by blood trough concentrations
changes in liver function during and adjust tacrolimus dose if
DAA therapy, related to clearance needed to ensure continued
of hepatitis virus. A decrease in efficacy and safety.
tacrolimus blood levels may occur.
However, the CYP3A4 inhibiting
potential of some DAAs may
counteract that effect or lead to
increased tacrolimus blood levels.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) cimetidine (HOS-085835) methylprednisolone (HOS-088374) metoclopramide (HOS-090626) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 68abbc0e81b1437bff868430435451d7917ce74f1d4d423331973d9ec54e919f · Zeichen 13741–16926 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.